Goldman Sachs
IMCR icon

Goldman Sachs’s Immunocore IMCR Stock Holding History

Goldman Sachs’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-46,700
Closed -$3.04M – 5781
2024
Q1 		$3.04M Buy
+46,700
New +$3.2M ﹤0.01% 3532
2023
Q4 		– Sell
-7,200
Closed -$374K – 5722
2023
Q3 		$374K Buy
+7,200
New +$426K ﹤0.01% 4792

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Goldman Sachs's IMCR Position: Q1 2026 in Review

Goldman Sachs increased its Immunocore (IMCR) stake by 269% in Q1 2026, buying an estimated $2.82M and bringing the position to 119,497 shares worth $3.6M. The position accounts for ﹤0.01% of the portfolio, ranked #4006.

Goldman Sachs first reported a position in IMCR in Q4 2022 and has held it in 14 quarters since. The position peaked at $7.05M in Q3 2024. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Goldman Sachs held 119,497 shares of Immunocore worth $3.6M as of Q1 2026.
  • Goldman Sachs bought 87,107 Immunocore shares in Q1 2026, an estimated $2.82M.
  • Immunocore made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4006 holding.
  • Goldman Sachs first reported a position in Immunocore in Q4 2022 and has held it in 14 quarters since.
  • Goldman Sachs's Immunocore position peaked at $7.05M in Q3 2024.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.